Alzheimer’s Research UK is committing nearly £300,000 (~€341,000) for a landmark phase II clinical trial of Sativex®, a cannabis-based medicine licensed in the UK.
The UK’s leading dementia research charity, Alzheimer’s Research UK, has announced it will fund a revolutionary clinical trial at King’s College London, UK, investigating a cannabis-based medicine treatment for individuals living with dementia.
Approximately half of the 850,000 people living with dementia will experience symptoms of agitation or aggression. This can typically be one of the most challenging characteristics of the illness, both for the individual with dementia and those caring for them.
Alzheimer’s Research UK is dedicating nearly £300,000 (~€341,000) for a ground-breaking phase II clinical trial of Sativex®, a cannabis-based medicine licensed in the UK for the treatment of muscle stiffness and tightness experienced by people with multiple sclerosis.
However, Sativex® is not currently licensed in the UK for any
... read more at: https://www.healtheuropa.eu/cannabis-based-medicine/90321/